Svb Leerink Begins Coverage on Tocagen (TOCA)

Investment analysts at Svb Leerink initiated coverage on shares of Tocagen (NASDAQ:TOCA) in a research note issued to investors on Monday, Briefing.com Automated Import reports. The firm set a “market perform” rating and a $11.00 price target on the stock. Svb Leerink’s target price points to a potential upside of 8.70% from the stock’s previous close.

A number of other equities analysts also recently commented on the company. Leerink Swann began coverage on Tocagen in a report on Monday. They set a “market perform” rating and a $10.26 target price for the company. Zacks Investment Research downgraded Tocagen from a “buy” rating to a “hold” rating in a report on Wednesday, February 27th. Robert W. Baird began coverage on Tocagen in a report on Friday, January 18th. They issued an “outperform” rating and a $20.00 target price on the stock. Finally, B. Riley began coverage on Tocagen in a research note on Monday, December 31st. They issued a “buy” rating and a $22.00 price objective on the stock. Three equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $18.58.

Shares of Tocagen stock traded down $0.14 during midday trading on Monday, reaching $10.12. 1,332 shares of the company’s stock traded hands, compared to its average volume of 132,802. The company has a quick ratio of 5.91, a current ratio of 5.91 and a debt-to-equity ratio of 0.45. The company has a market cap of $236.19 million, a PE ratio of -4.12 and a beta of 3.50. Tocagen has a 12 month low of $6.47 and a 12 month high of $15.80.

Tocagen (NASDAQ:TOCA) last announced its earnings results on Wednesday, February 27th. The company reported ($0.96) EPS for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.35). The business had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.01 million. Tocagen had a negative net margin of 271.43% and a negative return on equity of 92.56%. On average, research analysts anticipate that Tocagen will post -2.94 earnings per share for the current year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TOCA. BlackRock Inc. grew its position in shares of Tocagen by 6.2% in the fourth quarter. BlackRock Inc. now owns 1,501,501 shares of the company’s stock valued at $12,327,000 after purchasing an additional 88,216 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Tocagen by 14.9% in the 3rd quarter. Vanguard Group Inc. now owns 787,550 shares of the company’s stock valued at $12,278,000 after purchasing an additional 101,874 shares in the last quarter. Vanguard Group Inc boosted its holdings in Tocagen by 14.9% in the 3rd quarter. Vanguard Group Inc now owns 787,550 shares of the company’s stock valued at $12,278,000 after purchasing an additional 101,874 shares in the last quarter. Foresite Capital Management III LLC boosted its holdings in Tocagen by 347.8% in the 4th quarter. Foresite Capital Management III LLC now owns 665,219 shares of the company’s stock valued at $5,461,000 after purchasing an additional 516,667 shares in the last quarter. Finally, Citigroup Inc. boosted its holdings in Tocagen by 1,917.8% in the 4th quarter. Citigroup Inc. now owns 457,246 shares of the company’s stock valued at $3,754,000 after purchasing an additional 434,585 shares in the last quarter. Institutional investors and hedge funds own 36.88% of the company’s stock.

About Tocagen

Tocagen Inc, a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells.

Further Reading: Balance Sheet

Analyst Recommendations for Tocagen (NASDAQ:TOCA)

Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply